Michal Solomon1, Eli Schwartz2, Felix Pavlotsky3, Nicole Sakka4, Aviv Barzilai3, Shoshana Greenberger3. 1. Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: solomondr1@gmail.com. 2. Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Abstract
BACKGROUND: Limited data are available regarding topical and systemic therapies for Leishmania tropica in children. OBJECTIVE: We sought to characterize the clinical presentation and evaluate the efficacy and safety of topical and systemic treatments in pediatric patients infected with L tropica. METHODS: A retrospective study was performed on 47 children with L tropica cutaneous leishmaniasis. Treatments included topical or systemic therapy with liposomal amphotericin B or pentavalent antimony. RESULTS: Seventy patients with L tropica cutaneous leishmaniasis were treated at our center between 2008 and 2012, of which 47 (67%) were children. The average age of the pediatric population was 8.8 years, and the face was the most common site of involvement (76%). The average number of lesions was 2.6. 24 children (51%) required systemic therapy. The patients were treated with 3 to 5 mg/kg/d of intravenous liposomal amphotericin B, and a response was observed in 83% of the patients within 3 months. LIMITATIONS: This was a retrospective study. CONCLUSION: The disease burden of L tropica in children is high, and because of facial involvement and a low response to topical therapies, systemic therapy is often required. In our experience, liposomal amphotericin B treatment in children is safe and effective and is required for a considerably shorter duration than treatment with pentavalent antimony.
BACKGROUND: Limited data are available regarding topical and systemic therapies for Leishmania tropica in children. OBJECTIVE: We sought to characterize the clinical presentation and evaluate the efficacy and safety of topical and systemic treatments in pediatric patients infected with L tropica. METHODS: A retrospective study was performed on 47 children with L tropica cutaneous leishmaniasis. Treatments included topical or systemic therapy with liposomal amphotericin B or pentavalent antimony. RESULTS: Seventy patients with L tropica cutaneous leishmaniasis were treated at our center between 2008 and 2012, of which 47 (67%) were children. The average age of the pediatric population was 8.8 years, and the face was the most common site of involvement (76%). The average number of lesions was 2.6. 24 children (51%) required systemic therapy. The patients were treated with 3 to 5 mg/kg/d of intravenous liposomal amphotericin B, and a response was observed in 83% of the patients within 3 months. LIMITATIONS: This was a retrospective study. CONCLUSION: The disease burden of L tropica in children is high, and because of facial involvement and a low response to topical therapies, systemic therapy is often required. In our experience, liposomal amphotericin B treatment in children is safe and effective and is required for a considerably shorter duration than treatment with pentavalent antimony.
Authors: Dirk Debus; Semra Genç; Philipp Kurz; Martin Holzer; Kurt Bauer; Ralph Heimke-Brinck; Martin Baier; Heidi Sebald; Andrea Debus; Christian Bogdan; Kurt-Wilhelm Stahl Journal: Am J Trop Med Hyg Date: 2022-01-10 Impact factor: 3.707
Authors: Mustafa Aksoy; Nebiye Doni; Hatice Uce Ozkul; Yavuz Yesilova; Nurittin Ardic; Abdullah Yesilova; Jennifer Ahn-Jarvis; Steve Oghumu; Cesar Terrazas; Abhay R Satoskar Journal: PLoS Negl Trop Dis Date: 2016-07-14